To view this email as a web page, click here.

Bias for Patient-Reported Outcomes in Open-Label Cancer Trials: How Big of a Concern Is It?

The US Food and Drug Administration explored the possibility of such bias in a recent viewpoint published in JAMA Oncology. Read more

Podcast: Emerging Immunotherapy Approaches For Urothelial Cancer

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer. Read more

IN CASE YOU MISSED IT

ARCHES Trial "Changes Practice" for Metastatic Hormone-Sensitive Prostate Cancer

Researchers found that the HSD3B1 genotype may be a predictive biomarker for the use of certain prostate cancer therapies.

Read more

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.